Ionis Pharmaceuticals, which recently announced it will open a sprawling research-and-development center in Oceanside, also plans a large expansion of its home base in Carlsbad.
About 20% of the global population and one in five U.S. adults have elevated levels of lipoprotein(a), a complex form of LDL that strongly predicts risk for coronary disease and aortic valve stenosis. Evidence for a causal association between Lp(a) concentration, which is primarily genetically determined, and CV outcomes across ethnicities continues to build.
Ionis Pharmaceuticals, the California company that turned RNA-targeting medicines from an unproven idea into blockbuster drugs, is now expanding into a new class of therapeutics that treat disease by editing DNA.
Ionis Pharmaceuticals has formed an alliance with gene editing startup Metagenomi in a bid to branch out beyond the RNA-based drugs it’s known for.